Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 4/20 | 0.36 |
| ▸ | MME | P08473 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | F7 | P08709 | 1/20 | 0.35 |
| ▸ | F3 | P13726 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1996571 | 1.00 | XIAP (0.44) | XIAPKMT2ATSHRMEN1MAPT | |
| SCHEMBL2004057 | 0.90 | XIAP (0.48) | XIAPKMT2ATSHRMEN1ALDH1A1 | |
| SCHEMBL2004060 | 0.90 | XIAP (0.48) | XIAPKMT2ATSHRMEN1ALDH1A1 | |
| SCHEMBL2279348 | 0.82 | NPY1R (0.45) | XIAPKMT2AMEN1ACEMME | |
| SCHEMBL2236369 | 0.81 | KMT2A (0.44) | XIAPKMT2ATSHRMEN1MAPT | |
| SCHEMBL1999440 | 0.78 | RIPK1 (0.42) | XIAPKMT2AMEN1TP53SMN1; SMN2 | |
| SCHEMBL1999442 | 0.78 | RIPK1 (0.42) | XIAPKMT2AMEN1TP53SMN1; SMN2 | |
| SCHEMBL3157917 | 0.77 | XIAP (0.56) | XIAPTSHRACEMMEF2 | |
| SCHEMBL3157911 | 0.77 | XIAP (0.56) | XIAPTSHRACEMMEF2 | |
| SCHEMBL5223108 | 0.76 | TSHR (0.49) | XIAPKMT2ATSHRMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960373-B2 | 2-alkoxy-3,4,5-trihydroxyalkylamide-benzothiazepines preparation thereof, compositions containing them and use thereof | SANOFI-AVENTIS (FR) | 2011-06-14 | — | — | US | disclosed |
| US-20070244087-A1 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDES, PREPARATION THEREOF, COMPOSITIONS CONTAINING THEM AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244087-A1 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDES, PREPARATION THEREOF, COMPOSITIONS CONTAINING THEM AND USE THEREOF | HCCS, ALKBH2, ALKBH3 | XIAP 643/4885KMT2A 203/4885TSHR 4201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.